GlassScriptPhysician profile
Lauren C Sharon
NPI 1932213766
$1,306.85
in general payments reported to CMS, 2019-2025
25 companies · $390 in 2025
The $390 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $199 · 2023: $347 · 2024: $371 · 2025: $390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,108.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $371.60 | 2023-2025 | Reblozyl, Opdivo, Opdualag |
| Abbvie INC. | $111.24 | 2024-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $87.39 | 2022-2023 | Imbruvica |
| Janssen Biotech, INC. | $80.39 | 2022-2024 | Talvey |
| Novartis Pharmaceuticals Corporation | $65.40 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $63.43 | 2025 | Opdivo |
| Pfizer INC. | $62.09 | 2024-2025 | |
| Myovant Sciences INC. | $46.64 | 2022 | |
| Beigene USA, INC. | $41.58 | 2023-2024 | Brukinsa |
| Astrazeneca Pharmaceuticals LP | $34.77 | 2024 | Enhertu |
| Csl Behring | $34.75 | 2023 | Idelvion, Afstyla |
| Jazz Pharmaceuticals INC. | $32.72 | 2025 | |
| Genentech USA, INC. | $30.92 | 2022-2023 | Venclexta |
| Adc Therapeutics America, INC. | $29.61 | 2024-2025 | |
| Genzyme Corporation | $26.39 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $25.35 | 2023 | |
| Karyopharm Therapeutics INC. | $23.69 | 2022 | |
| Tersera Therapeutics LLC | $21.77 | 2024 | Zoladex |
| Gilead Sciences, INC. | $19.33 | 2024 | |
| Emd Serono, INC. | $18.18 | 2025 | |
| Astellas Pharma US INC | $17.72 | 2025 | Padcev |
| Beone Medicines USA, INC. | $17.14 | 2025 | Tevimbra |
| Glaxosmithkline, LLC. | $17.11 | 2024 | Ojjaara |
| Sumitomo Pharma America, INC. | $15.85 | 2024 | Orgovyx |
| Adaptive Biotechnologies Corporation | $11.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Sharon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.